This year, something rather horrific has happened to me. For years, I have mocked friends and family for suffering from hay fever, while I have otherwise been immune. But karma has caught up with me. I, too, am now apparently allergic to pollen.
But why? For a good three decades, I have been completely fine. Suddenly, this summer I was struck with runny noses and crying eyes at random moments. And it appears I’m not alone in developing adult-onset allergies.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.